KLK3 and prostate carcinoma: Future research in the context of prostate cancer should focus on cancers where PSA is not yet detectable, i.e., immediately after primary treatment, and on more potent vaccine technologies than DNA vaccines encoding prostate-specific antigens in combination with checkpoint blockade.